Cullen Frost Bankers Inc. bought a new stake in DENTSPLY SIRONA Inc (NASDAQ:XRAY) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 2,107 shares of the medical instruments supplier’s stock, valued at approximately $104,000.
A number of other hedge funds also recently modified their holdings of the business. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of DENTSPLY SIRONA during the fourth quarter worth approximately $26,000. Private Capital Group LLC boosted its position in shares of DENTSPLY SIRONA by 105.3% during the fourth quarter. Private Capital Group LLC now owns 700 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 359 shares during the period. Pinnacle Bank acquired a new position in shares of DENTSPLY SIRONA during the fourth quarter worth approximately $26,000. Truehand Inc acquired a new position in shares of DENTSPLY SIRONA during the fourth quarter worth approximately $27,000. Finally, Enlightenment Research LLC acquired a new position in shares of DENTSPLY SIRONA during the fourth quarter worth approximately $30,000. Institutional investors own 91.69% of the company’s stock.
Several equities analysts have recently issued reports on the company. ValuEngine upgraded DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a research report on Saturday, May 4th. HC Wainwright reiterated a “neutral” rating and set a $55.00 price objective (up from $49.00) on shares of DENTSPLY SIRONA in a research report on Monday, May 6th. Barrington Research upgraded DENTSPLY SIRONA from a “market perform” rating to an “outperform” rating and set a $63.00 price objective for the company in a research report on Monday, May 6th. Zacks Investment Research upgraded DENTSPLY SIRONA from a “hold” rating to a “buy” rating and set a $61.00 price objective for the company in a research report on Saturday, May 11th. Finally, BidaskClub upgraded DENTSPLY SIRONA from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 15th. Nine investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $53.62.
In related news, Director Gregory T. Lucier purchased 10,000 shares of the company’s stock in a transaction on Thursday, May 23rd. The shares were bought at an average price of $53.60 per share, with a total value of $536,000.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $536,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Eric Brandt sold 9,160 shares of the company’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $53.45, for a total value of $489,602.00. Following the completion of the transaction, the director now directly owns 26,003 shares in the company, valued at approximately $1,389,860.35. The disclosure for this sale can be found here. In the last three months, insiders have sold 123,922 shares of company stock worth $6,790,905. 0.62% of the stock is owned by corporate insiders.
NASDAQ:XRAY traded up $0.06 during midday trading on Wednesday, hitting $53.72. 2,088,498 shares of the stock were exchanged, compared to its average volume of 1,869,180. DENTSPLY SIRONA Inc has a one year low of $33.93 and a one year high of $55.88. The stock has a market cap of $12.58 billion, a price-to-earnings ratio of 26.73, a PEG ratio of 2.00 and a beta of 1.11. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.06 and a quick ratio of 1.35.
DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Friday, May 3rd. The medical instruments supplier reported $0.49 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.39 by $0.10. DENTSPLY SIRONA had a positive return on equity of 8.99% and a negative net margin of 26.48%. The firm had revenue of $946.20 million for the quarter, compared to analysts’ expectations of $925.13 million. During the same quarter in the previous year, the company earned $0.45 earnings per share. The firm’s quarterly revenue was down 1.0% compared to the same quarter last year. On average, sell-side analysts expect that DENTSPLY SIRONA Inc will post 2.34 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, July 12th. Investors of record on Friday, June 28th will be issued a dividend of $0.0875 per share. This is a boost from DENTSPLY SIRONA’s previous quarterly dividend of $0.09. The ex-dividend date is Thursday, June 27th. This represents a $0.35 annualized dividend and a yield of 0.65%. DENTSPLY SIRONA’s payout ratio is presently 17.41%.
ILLEGAL ACTIVITY NOTICE: This story was published by Sundance Herald and is the sole property of of Sundance Herald. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://sundanceherald.com/2019/05/29/cullen-frost-bankers-inc-takes-position-in-dentsply-sirona-inc-xray.html.
About DENTSPLY SIRONA
DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
Further Reading: 52-Week High/Low
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.